Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with BRCA1/2-associated breast cancer have good survival outcomes and are living longer, but this raises the ...

Do you have any thoughts about the effect of oral contraceptives on tubo-ovarian cancer risk in BRCA1/2 mutation carriers? Based on the observed age of onset of these tubo-ovarian cancers ...

Germline BRCA 1 and BRCA 2 test results were available for all 450 men. These revealed 27 germline BRCA2 variants (6%), but only two germline BRCA1 variants (0.5%), and one of these probably wasn ...

The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, ...

Selecting the most appropriate risk-reducing strategy is not a straightforward task. The impact of risk-reducing strategies on cancer risk, survival, and overall quality of life are the key ...

Women with BRCA1 or BRCA2 mutations have a very high lifetime risk of developing breast and ovarian cancer. Women have options to reduce their risk of cancer. Options to reduce breast cancer risk ...

This ability is similar to the action of the first drugs approved to target BRCA1/2 deficient cancers, the so-called PARP (poly-ADP-ribose polymerase) inhibitors, which are now in clinical use.

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

by 47% compared to standard of care in untreated mCRPC patients with BRCA1/2 mutations. However, Akeega failed to improve rPFS compared to Zytiga alone in mCRPC patients without homologous ...

Recent investigation focuses on the effects of BRCA1 and BRCA2 tumor pathogenic variants (tPVs) within the parameters of two ...

Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations. In this combination trial patients were ...